Pharma R&D Pipeline · 2026

Chief Scientific Officer · 42 active programs · $1.4B budget · cycle: 2026
Active Programs
42▲4vs LY
Phase 3 Programs
6▲2vs LY
Pipeline NPV
$8.4B▲12%vs LY
Avg Time to Market
11.4 yr▲0.4 yrvs LY

R&D pipeline funnel · with success probability

Discovery → Approval · attrition at each phase · industry success rate ~10% from Phase 1

Top 8 programs · swim-lane timeline

Each row = molecule · color = current phase · segment width = duration

Therapeutic area mix · pipeline value

Where the NPV lives · Oncology dominant

Phase progression · success probability

Industry benchmarks · cumulative odds Discovery → Approval